| Assessment Status | Rapid Review Complete |
| HTA ID | 25029 |
| Drug | Daridorexant |
| Brand | Quviviq® |
| Indication | Daridorexant (Quviviq®) for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning. |
| Assessment Process | |
| Rapid review commissioned | 01/04/2025 |
| Rapid review completed | 25/04/2025 |
| Rapid review outcome | The NCPE recommends that a full HTA is recommended to assess the clinical effectiveness and cost effectiveness of daridorexant compared with the current standard of care*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.
Further information on the status of this decision may be found here.
